GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » 10-Year RORE %

Zosano Pharma (Zosano Pharma) 10-Year RORE % : 0.00% (As of Mar. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Zosano Pharma does not have enough data to calculate 10-Year RORE %.


Zosano Pharma 10-Year RORE % Historical Data

The historical data trend for Zosano Pharma's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma 10-Year RORE % Chart

Zosano Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zosano Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zosano Pharma's 10-Year RORE %

For the Biotechnology subindustry, Zosano Pharma's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zosano Pharma's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zosano Pharma's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Zosano Pharma's 10-Year RORE % falls into.



Zosano Pharma 10-Year RORE % Calculation

Zosano Pharma's 10-Year RORE % for the quarter that ended in Mar. 2022 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2022 and 10-year before.


Zosano Pharma  (OTCPK:ZSANQ) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Zosano Pharma 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zosano Pharma (Zosano Pharma) Business Description

Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
Christine Matthews officer: Chief Financial Officer C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo director, officer: Chief Executive Officer C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman officer: VP, Clinical Dev & Med Affairs INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang director C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse director 3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis officer: See Remarks C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos director 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Zosano Pharma (Zosano Pharma) Headlines

From GuruFocus

Zosano Pharma Provides Corporate Update

By GuruFocusNews GuruFocusNews 04-29-2022